This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 5
  • /
  • Omeros announces preliminary results from addition...

Omeros announces preliminary results from additionally critically ill COVID 19 patients treated with narsoplimab.

Read time: 1 mins
Published:30th May 2021
Omeros Corporation announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. These patients were part of the “second surge” of COVID-19 in Italy.

Narsoplimab is the company’s lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement. “The COVID-19 patients in this group were even sicker than those in the first cohort of patients treated with narsoplimab at our institution during the pandemic’s outbreak,” said Alessandro Rambaldi, MD, Professor, Department of Oncology and Hematology-Oncology at the University of Milan and Head of the Hematology and Bone Marrow Transplant Unit at ASST Papa Giovanni XXIII in Bergamo, Italy. “All of the patients had significant ARDS with 90 percent of them intubated at the start of narsoplimab treatment, the majority had multiple comorbidities and risk factors for poor outcome, and all had failed other therapies. The results in these patients are outstanding and further support what we have learned about the pathophysiology of COVID-19, the central role of endothelial damage in the disease, and the mechanism of action of narsoplimab.” The patients were treated under compassionate use at ASST Papa Giovanni XXIII Hospital between October 2020 and April 2021. Highlights of the study are as follows: Baseline characteristics of the 10 study patients :Median age: 65 years (range 41 to 79 years), 90% were men, all had comorbidities/risk factors for poor outcome (i.e., diabetes, cardiovascular disease/hypertension, overweight/obese, dyslipidemia) Acute respiratory distress syndrome (ARDS) severity (by Berlin criteria) at time of intubation or ICU admission: 80% severe, 20% moderate, all had failed other therapies (steroids). Narsoplimab treatment : 90% were intubated at initiation of narsoplimab treatment. Narsoplimab was administered intravenously twice weekly; median doses administered: 6 (range 3 to 8 doses). Results :i. 80% recovered, survived and were discharged. ii. 2 deaths-76-year-old man from complications of pre-existing cardiomyopathy; received 3 doses of narsoplimab. 68-year-old man from multi-organ failure; narsoplimab dosing was initiated after 13 days of intubation. Omeros plans to publish detailed data from the study in a peer-reviewed scientific journal.

Condition: Coronavirus/ARDS
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.